PMID- 2174783
OWN - NLM
STAT- MEDLINE
DCOM- 19910124
LR  - 20190813
IS  - 0031-6970 (Print)
IS  - 0031-6970 (Linking)
VI  - 39
IP  - 2
DP  - 1990
TI  - Dose adjusted heparin treatment of deep venous thrombosis: a comparison of 
      unfractionated and low molecular weight heparin.
PG  - 107-12
AB  - Two studies have been done to establish recommendations for dosage and dose 
      adjustment in the treatment of deep vein thrombosis (DVT) with low molecular 
      weight heparin (LMWH). In the first, 56 patients were randomized in a double 
      blind study to be treated either with unfractionated heparin (UFH) or LMWH s.c. 
      every 12 h. Initial doses were given according to age and sex, disregarding 
      bodyweight, and the dose was then adjusted when the peak plasma heparin 
      concentration fell outside the desired range of 0.5-0.8 anti-FXa U/ml. There were 
      fewer dose adjustments in the LMWH group. The correlation between injected dose 
      (U/kg bodyweight) and the heparin concentration was higher in the LMWH group (r = 
      0.59) than in the UFH group (r = 0.38). The results suggest that, in order to 
      obtain the desired heparin concentration, the initial dose of LMWH should be 
      about 100 U/kg bodyweight every 12 h. In the second, open study, this dosage plan 
      was followed in 15 patients. The peak heparin concentration on Day 2 ranged from 
      0.40 to 0.75 anti-FXa U/ml and adjustment was only required in 3 patients. Day to 
      day variation in peak heparin activity in the individual patient varied little 
      (CV 11-22%), and there was no accumulation. The results indicate that plasma 
      heparin concentration is more predictable using LMWH than UFH, and they point to 
      definite advantages in the use of LMWH in a bodyweight adjusted dosage.
FAU - Handeland, G F
AU  - Handeland GF
AD  - Medical Department, Aker Hospital, Oslo, Norway.
FAU - Abildgaard, U
AU  - Abildgaard U
FAU - Holm, H A
AU  - Holm HA
FAU - Arnesen, K E
AU  - Arnesen KE
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - Germany
TA  - Eur J Clin Pharmacol
JT  - European journal of clinical pharmacology
JID - 1256165
RN  - 0 (Heparin, Low-Molecular-Weight)
RN  - 9005-49-6 (Heparin)
SB  - IM
MH  - Aged
MH  - Double-Blind Method
MH  - Female
MH  - Heparin/administration & dosage/blood/*therapeutic use
MH  - Heparin, Low-Molecular-Weight/administration & dosage/blood/*therapeutic use
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Thrombophlebitis/*drug therapy
EDAT- 1990/01/01 00:00
MHDA- 1990/01/01 00:01
CRDT- 1990/01/01 00:00
PHST- 1990/01/01 00:00 [pubmed]
PHST- 1990/01/01 00:01 [medline]
PHST- 1990/01/01 00:00 [entrez]
AID - 10.1007/BF00280041 [doi]
PST - ppublish
SO  - Eur J Clin Pharmacol. 1990;39(2):107-12. doi: 10.1007/BF00280041.